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Okayama University research: Diabetes drug helps towards immunity against cancer 
  
(Okayama, 23 March) Studies reveal how a diabetes drug helps towards the rejection of  
tumours by supporting immune cells. 
 
A 30-40% decrease in the risk of cancer has been observed in patients using the drug 
metformin to treat diabetes 2. This characteristic is in striking contrast with insulin-based 
diabetes treatments, which are linked to increases in cancer, however the mechanism 
behind metformin’s anticancer effects has so far not been well understood. Now Heiichiro 
Udono and colleagues at Okayama University and Kawasaki University in Japan explain 
these anticancer responses in a report investigating the drug’s effects on the immune 
system’s T cells.  
 
The researchers tested the effects of dissolving metformin in the drinking water of mice 
injected with leukaemia cells and confirmed complete rejection of the tumours. When the 
mice were subsequently re-injected with twice the amount of cancer cells, no tumours 
formed suggesting an immunologic memory response. Renal and skin cancers also 
responded to the treatment and low doses similar to diabetes prescription concentrations 
were still effective for tumour rejection. Further experiments with mice lacking certain cell 
types showed that the influence of metformin on CD8+ T cells in particular was responsible 
for the anticancer effects.  
 
During chronic diseases including cancer, CD8+ T cells undergo a process called ‘immune 
exhaustion’, where after repeated antigen (Ag) stimulation the cells can no longer secrete 
chemicals crucial for the immune system to function. ‘Apoptosis’ or cell death of these 
exhausted T cells ensues. The researchers incubated isolated T cells and found that CD8+ T 
cells from metformin-treated mice still produced immune response chemicals.  
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Further comparisons revealed specific memory characteristics and protein producing 
abilities in the T cells of metformin treated mice. “These findings provide novel insights into 
anticancer immunity,” conclude the researchers in a report of their results. Further work is 
needed to study the effects on different types of tumours and to clarify the specific cellular 
and molecular mechanisms involved.  
 
Background 
About metformin 
Metformin is antihyperglycemic, and so counters insulin resistance. Early use has been 
shown to increase survival in patients either suffering from obesity-involved type 2 diabetes 
or cardiovascular disease or both. 
 
The observed anticancer effects triggered further epidemiological studies that confirmed a 
30-40% reduction in cancer risk for patients treated with metformin. It was further shown to 
reduce cancer in a breast cancer mouse model and to increase life expectancy. However 
while the mechanism seemed to stem from destruction of cancer initiating cells, until now 
the mechanism was unclear. 
 
Immune exhaustion 
White blood cells in the immune system help protect the body against disease. T cells are a 
particular type of white blood cell that fight infection by activating cells to release cytotoxic 
cytokines – small proteins - and signalling chemicals instead of involving antibodies. 
 
CD8+ are cytotoxic T cells that destroy virus cells and cancer tumours. However as cancer 
cells and pathogens repeatedly stimulate CD8+, they eventually lose their ability to secrete 
the signalling chemicals that cause cell death and regulate the immune system such as 
interleukin 2 (IL-2), tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ). These 
chemicals continued to be produced by T cells isolated from metformin-treated mice.  
 
In addition CD8+ cells in diseased organisms undergo phenotypic changes to express 
exhaustion markers causing the cell death processes of apoptosis to ensue. Blocking these 
markers has been studied as a means to tumour rejection and further studies are underway 
to investigate T-cell exhaustion management in tumour immunotherapy.  
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Memory T cells 
T cells that have encountered a disease or cancer can respond more quickly when faced 
with the same pathogen a second time. This improved ‘memory response’ on second 
encounter was observed in the metformin study.  
Although these ‘memory T cells’ are not yet well understood, a classification model has 
been proposed on the basis of acute viral studies. The model includes two types: central 
memory (TCMs) and effector memory (TEMs).  The researchers studied the proportions of 
TEMs and TCMs in tumour infiltrating white blood cells with and without metformin. They 
found that TEM cells played a more significant role in tumour rejection. 
 
 
Figure caption 
Metformin improves the multifunctionality of antigen-specific CD8+ T cells in vivo. Mice 
inoculated with 2 × 105  melanoma cells were treated with or without metformin from day 7, 
as indicated by the shadowed rectangle, and tumour growth was monitored. The results are 
representative of two independent experiments. n = 5 per group.  
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Further information 
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1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan 
Planning and Public Information Division, Okayama University 
E-mail: www-adm@adm.okayama-u.ac.jp 
Website: http://www.okayama-u.ac.jp/index_e.html 
Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/ 
Okayama Univ. e-Bulletin (PDF Issues): http://www.okayama-
u.ac.jp/en/tp/cooperation/ebulletin.html 
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYI 
Okayama University Image Movie (You Tube): 
https://www.youtube.com/watch?v=_WnbJVk2elA 
 
Okayama University Medical Research Updates （OU-MRU） 
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells 
from blood samples for genetic testing 
Vol.2：Ensuring a cool recovery from cardiac arrest 
Vol.3：Organ regeneration research leaps forward 
Vol.4：Cardiac mechanosensitive integrator 
Vol.5：Cell injections get to the heart of congenital defects 
Vol.6：Fourth key molecule identified in bone development 
Vol.7：Anticancer virus solution provides an alternative to surgery 
Vol.8：Light-responsive dye stimulates sight in genetically blind patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
About Okayama University 
Okayama University is one of the largest 
comprehensive universities in Japan with 
roots going back to the Medical Training 
Place sponsored by the Lord of Okayama 
and established in 1870. Now with 1,300 
faculty and 14,000 students, the University 
offers courses in specialties ranging from 
medicine and pharmacy to humanities 
a n d  p h y s i c a l  s c i e n c e s .  O k a y a m a 
University is located in the heart of Japan 
approximately 3 hours west of Tokyo by 
Shinkansen. 
